Cytogenetic alterations in prostate cancer [Zytogenetische veranderungen des prostatakarzinoms]

被引:0
|
作者
Sauter G. [1 ,3 ]
Bubendorf L. [1 ]
Moch H. [1 ]
Gasser Th.C. [2 ]
Mihatsch M.J. [1 ]
机构
[1] Institut fur Pathologie, Universitatskliniken, Kantonsspital Basel, CH-4003 Basel
来源
Der Pathologe | 1998年 / 19卷 / 1期
关键词
Cytogenetics; Gene amplification; Polysomy; Prostate cancer;
D O I
10.1007/s002920050256
中图分类号
学科分类号
摘要
Development and progression of tumors is driven by a malfunction of specific genes. Although prostate cancer is one of the most frequent tumors, little is known about the genes involved. Cytogenetic and molecular examinations have shown that chromosomal deletions most frequently involve 7q, 8p, 10q, 13q, 16q, 17p and the Y chromosome. These loci may carry tumor suppressor genes with relevance for prostate cancer. DNA sequence copy number gains were most frequently observed at chromosomes 7, 8q, and 11q. These regions may carry currently unknown oncogenes. There is increasing evidence for a clinical relevance of genetic alterations. Polysomies of several chromosomes were shown to be associated with poor prognosis of prostate cancer patients. Androgen receptor amplification can be found in hormone- refractory carcinomas which may respond to total androgen blockage. For the future it is hoped that the identification of the genes involved in prostate cancer and the determination of their function could allow for significant improvements of treatment strategies for prostate cancer patients.
引用
收藏
页码:63 / 68
页数:5
相关论文
共 50 条
  • [1] Chemotherapy of prostate cancer [Chemotherapie des Prostatakarzinoms]
    Ohlmann C.-H.
    Der Urologe, 2015, 54 (10): : 1461 - 1470
  • [2] Brachytherapy of the prostate cancer [Brachytherapie des prostatakarzinoms]
    Stübinger S.H.
    Wilhelm R.
    Kaufmann S.
    Döring M.
    Hautmann S.
    Jünemann K.P.
    Galalae R.
    Der Urologe, 2008, 47 (3): : 284 - 290
  • [3] Cryoablation of prostate cancer [Kryoablation des Prostatakarzinoms]
    Witzsch U.K.F.
    Becht E.
    Der Urologe, 2015, 54 (2): : 191 - 201
  • [4] Chemoprevention of prostate cancer [Chemoprävention des prostatakarzinoms]
    Djavan B.
    Thompson I.
    Michel M.S.
    Waldert M.
    Seitz C.
    Der Urologe, Ausgabe A, 2004, 43 (5): : 557 - 561
  • [5] Epidemiologie des Prostatakarzinoms in DeutschlandEpidemiology of prostate cancer in Germany
    Silke Hermann
    Klaus Kraywinkel
    Der Onkologe, 2019, 25 (4): : 294 - 303
  • [6] Cytogenetic alterations in prostate cancer
    Sauter, G
    Bubendorf, L
    Moch, M
    Gasser, TC
    Mihatsch, MJ
    PATHOLOGE, 1998, 19 (01): : 63 - 68
  • [7] Differential therapy of prostate cancer [Differenzialtherapie des prostatakarzinoms]
    Jäger T.
    Rübben H.
    Börgermann C.
    Der Internist, 2007, 48 (12): : 1382 - 1388
  • [8] Cryoablation of prostate cancer [Die kryoablation des prostatakarzinoms]
    Witzsch U.K.F.
    Skriapas K.
    Becht E.
    Der Urologe, 2008, 47 (4): : 449 - 454
  • [9] Diagnostic histopathology of prostate cancer [Diagnostische Histopathologie des Prostatakarzinoms]
    Kristiansen G.
    Der Urologe, 2013, 52 (7): : 933 - 941
  • [10] Fokale Therapie des Prostatakarzinoms in DeutschlandFocal therapy of prostate cancer in Germany
    M. Apfelbeck
    A. Herlemann
    C. G. Stief
    C. Gratzke
    Der Urologe, 2016, 55 (5): : 584 - 592